Bavarian Nordic granted European approval of monkeypox vaccine
On Friday, the EMA’s expert committee recommended broadening the vaccine’s label, which already listed smallpox, to include monkeypox. The EU Commission has acted expeditiously, officially authorizing it today.
by marketwire, translated by daniel pedersen
On Monday, the EU Commission officially extended the indication of Bavarian Nordic’s smallpox vaccine, Imvanex, to also include monkeypox, the firm announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Needham lifts Bavarian Nordic's target stock price 13%
For subscribers
